|
Balance Sheet Cash Flow Statement 2215 Bridgepointe Pkwy., Ste. 200 San Mateo, CA 94404 CA Tel. 650-358-3300 Fax 650-649-1798 |
Type: Public
On the web:
http://www.neurogesx.com
Employees:
42
NeurogesX is paving the way for treating neuropathic pain, or chronic pain caused by damaged nerves. The company's lead candidate is Qutenza (formerly known as NGX-4010), a skin patch that uses a synthetic version of capsaicin (an ingredient in hot peppers) to lessen nerve pain. NeruogesX has been developing the drug in the US and Europe for a number of pain indications, including post-herpetic neuralgia (caused by shingles), diabetic neuropathy, and neuropathic pain associated with HIV. However, the drug is furthest advanced in the US as a treatment for post-herpetic neuralgia. Other product candidates in the NeurogesX pipeline include a liquid formulation of synthetic capsaicin and an opioid pain reliever.
Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($26.0)M
Officers:
Chairman: Jean-Jacques (J.J.) Bienaimé
President, CEO, and Director: Anthony A. (Tony) DiTonno
CFO: Stephen F. Ghiglieri
Competitors:
Eli Lilly
Endo Pharmaceuticals
Pfizer
